Literature DB >> 11516098

Induction of chemoresistance in HL-60 cells concomitantly causes a resistance to apoptosis and the synthesis of P-glycoprotein.

M Campone1, F Vavasseur, M T Le Cabellec, K Meflah, F M Vallette, L Oliver.   

Abstract

The appearance of multidrug-resistant (MDR) proteins or the acquisition of a defective apoptotic programme are major drawbacks in the treatment of cancers since both induce a resistance to classical chemotherapy. However, a link between the two mechanisms has not, as yet, been clearly established. In this study, HL-60 cells cultured in the continual presence of a sub-lethal dose of doxorubicin (dox; HL-60/Dox) were used as a model to study acquired chemoresistance. During the induction of chemoresistance, the appearance of a functional P-glycoprotein (P-gp), in addition to the expression of anti-apoptotic Bcl-2, Bcl-XL and pro-apoptotic Bax proteins was assessed. Parental cells which are sensitive to dox, have no P-gp activity and express Bcl-2 and Bax. After 4 weeks of treatment, a functional P-gp was detected in HL-60/Dox cells. In addition, the synthesis of Bcl-2 appeared to be replaced by Bcl-XL while that of Bax remained unchanged. These cells were also resistant to apoptosis induced by both P-gp and non-P-gp substrates. This inability to induce apoptosis could have resulted from the induction of the expression of the inhibitor of apoptosis protein (XIAP). Our data show that acquired chemoresistance could involve a parallel induction of P-gp and an impairment of the apoptotic pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11516098     DOI: 10.1038/sj.leu.2402222

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  P-glycoprotein is not involved in pathway of anti-Fas/Fas-induced apoptosis in KBv200 cells.

Authors:  Qiu-Liang Wu; Xing-Ping Wu; Yong-Ju Liang; Li-Ming Chen; Yan Ding; Li-Wu Fu
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

2.  Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.

Authors:  Yun Xiang; Elizabeth R Remily-Wood; Vasco Oliveira; Danielle Yarde; Lili He; Jin Q Cheng; Linda Mathews; Kelly Boucher; Christopher Cubitt; Lia Perez; Ted J Gauthier; Steven A Eschrich; Kenneth H Shain; William S Dalton; Lori Hazlehurst; John M Koomen
Journal:  Mol Cell Proteomics       Date:  2011-08-16       Impact factor: 5.911

Review 3.  Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy.

Authors:  Subramanian Selvamuthukumar; Ramaiyan Velmurugan
Journal:  Lipids Health Dis       Date:  2012-11-20       Impact factor: 3.876

4.  Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.

Authors:  Yu-Li Lo; Yu Liu
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

Review 5.  Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2.

Authors:  Maria Gagliardi; Ana Tari Ashizawa
Journal:  Pharmaceutics       Date:  2022-01-01       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.